Clinical Trial Update: Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) [Phase 3]

View source ↗

Summary

The Phase 3 extension trial BOSTON-3 evaluating liposomal cyclosporine A added to standard of care for bronchiolitis obliterans syndrome in post-lung transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans
• Bronchiolitis Obliterans Syndrome

Drugs mentioned

• L-CsA (liposomal cyclosporine A)

Snippet

Sponsor: Zambon SpA | Conditions: Bronchiolitis Obliterans, Obliterative Bronchiolitis | Phase 3 | Status: TERMINATED